RKV Stock Discussion
Rakovina Therapeutics Inc Description
Rakovina Therapeutics, Inc., formerly Vincero Capital Corp., is a Canada-based company, which is engaged in developing cancer treatments based on DNA-damage response technologies. The Company’s lead product candidate is kt-2000 Next Generation PARP-inhibitors. Its pipeline includes kt-3000 Dual Action DDR-inhibitors and kt-4000 DNA Damaging DDR-inhibitors. Its kt-2000 series is a patented class of highly potent, oral inhibitors of poly (ADP-ribose) polymerase (PARP). Its kt-3000 drug candidates selectively inhibit secondary DDR pathways associated with treatment resistance and PARP. kt-4000 drug candidates release a potent DNA-damaging agent, while also inhibiting DDR to selectively kill cancer cells.
Industry: Biotechnology
Keywords: Cancer Biology Catalysts
Recent Comments
- Deaddog on Deaddog Trades; Go ahead ask questions.
- Cos3 on Deaddog Trades; Go ahead ask questions.
- Deaddog on Deaddog Trades; Go ahead ask questions.
- SwingTradeBot on Market Recap for Tuesday, February 27, 2024
- SwingTradeBot on Market Recap for Monday, February 26, 2024
From the Blog
Featured Articles